Marshall Wace’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $160M | Sell |
1,996,377
-3,929,250
| -66% | -$324M | 0.16% | 98 |
|
|
2025
Q4 | $505M | Buy |
5,925,627
+2,359,128
| +66% | +$194M | 0.46% | 29 |
|
|
2025
Q3 | $277M | Sell |
3,566,499
-3,329,080
| -48% | -$260M | 0.28% | 49 |
|
|
2025
Q2 | $539M | Buy |
6,895,579
+3,864,908
| +128% | +$288M | 0.61% | 17 |
|
|
2025
Q1 | $220M | Sell |
3,030,671
-2,782,748
| -48% | -$199M | 0.28% | 56 |
|
|
2024
Q4 | $430M | Buy |
5,813,419
+2,079,642
| +56% | +$146M | 0.52% | 21 |
|
|
2024
Q3 | $246M | Buy |
3,733,777
+3,659,111
| +4,901% | +$266M | 0.3% | 48 |
|
|
2024
Q2 | $6.9M | Sell |
74,666
-104,328
| -58% | -$9.24M | 0.01% | 873 |
|
|
2024
Q1 | $17.1M | Buy |
178,994
+75,973
| +74% | +$6.38M | 0.03% | 568 |
|
|
2023
Q4 | $7.86M | Sell |
103,021
-1,682,776
| -94% | -$117M | 0.01% | 752 |
|
|
2023
Q3 | $124M | Sell |
1,785,797
-2,777,940
| -61% | -$223M | 0.25% | 76 |
|
|
2023
Q2 | $430M | Sell |
4,563,737
-402,059
| -8% | -$34.9M | 0.84% | 11 |
|
|
2023
Q1 | $411M | Buy |
4,965,796
+811,769
| +20% | +$63.8M | 0.87% | 10 |
|
|
2022
Q4 | $310M | Buy |
4,154,027
+641,715
| +18% | +$49.5M | 0.7% | 14 |
|
|
2022
Q3 | $290M | Buy |
3,512,312
+2,199,410
| +168% | +$212M | 0.64% | 13 |
|
|
2022
Q2 | $125M | Buy |
1,312,902
+883,380
| +206% | +$91.5M | 0.26% | 77 |
|
|
2022
Q1 | $50.6M | Buy |
429,522
+248,806
| +138% | +$27.9M | 0.1% | 224 |
|
|
2021
Q4 | $23.4M | Buy |
180,716
+171,005
| +1,761% | +$19.9M | 0.04% | 438 |
|
|
2021
Q3 | $1.1M | Sell |
9,711
-17,904
| -65% | -$2.04M | ﹤0.01% | 1955 |
|
|
2021
Q2 | $2.86M | Sell |
27,615
-67,905
| -71% | -$6.4M | 0.01% | 1192 |
|
|
2021
Q1 | $7.99M | Buy |
+95,520
| New | +$8.08M | 0.04% | 567 |
|
|
2020
Q4 | – | Sell |
-38,145
| Closed | -$3.04M | – | 1950 |
|
|
2020
Q3 | $3.04M | Sell |
38,145
-1,415
| -4% | -$110K | 0.02% | 689 |
|
|
2020
Q2 | $2.73M | Sell |
39,560
-1,978
| -5% | -$141K | 0.02% | 671 |
|
|
2020
Q1 | $2.61M | Sell |
41,538
-168,657
| -80% | -$12.2M | 0.03% | 542 |
|
|
2019
Q4 | $16.3M | Buy |
210,195
+170,913
| +435% | +$13.3M | 0.11% | 199 |
|
|
2019
Q3 | $2.88M | Sell |
39,282
-192,675
| -83% | -$13.5M | 0.02% | 657 |
|
|
2019
Q2 | $14.3M | Buy |
231,957
+112,299
| +94% | +$6.79M | 0.12% | 198 |
|
|
2019
Q1 | $7.63M | Buy |
+119,658
| New | +$6.83M | 0.07% | 334 |
|
|
2018
Q3 | – | Sell |
-41,361
| Closed | -$2.01M | – | 1176 |
|
|
2018
Q2 | $2.01M | Buy |
+41,361
| New | +$1.93M | 0.03% | 428 |
|
|
2018
Q1 | – | Sell |
-33,321
| Closed | -$1.25M | – | 586 |
|
|
2017
Q4 | $1.25M | Buy |
33,321
+4,131
| +14% | +$152K | 0.05% | 229 |
|
|
2017
Q3 | $1.06M | Sell |
29,190
-3,306
| -10% | -$126K | 0.05% | 221 |
|
|
2017
Q2 | $1.28M | Sell |
32,496
-23,556
| -42% | -$860K | 0.06% | 167 |
|
|
2017
Q1 | $1.76M | Sell |
56,052
-2,083,917
| -97% | -$65.2M | 0.08% | 150 |
|
|
2016
Q4 | $66.8M | Buy |
2,139,969
+2,099,994
| +5,253% | +$68M | 0.44% | 52 |
|
|
2016
Q3 | $1.61M | Sell |
39,975
-20,310
| -34% | -$765K | 0.01% | 644 |
|
|
2016
Q2 | $2M | Sell |
60,285
-102,273
| -63% | -$3.5M | 0.02% | 586 |
|
|
2016
Q1 | $4.78M | Sell |
162,558
-108,375
| -40% | -$2.99M | 0.05% | 356 |
|
|
2015
Q4 | $7.13M | Buy |
270,933
+102,729
| +61% | +$2.67M | 0.07% | 305 |
|
|
2015
Q3 | $3.99M | Buy |
168,204
+69,354
| +70% | +$1.67M | 0.05% | 330 |
|
|
2015
Q2 | $2.35M | Buy |
98,850
+45,810
| +86% | +$1.03M | 0.03% | 438 |
|
|
2015
Q1 | $1.26M | Buy |
53,040
+41,064
| +343% | +$921K | 0.02% | 540 |
|
|
2014
Q4 | $254K | Sell |
11,976
-6,774
| -36% | -$136K | ﹤0.01% | 721 |
|
|
2014
Q3 | $319K | Hold |
18,750
| – | – | ﹤0.01% | 699 |
|
|
2014
Q2 | $268K | Sell |
18,750
-11,250
| -38% | -$153K | ﹤0.01% | 781 |
|
|
2014
Q1 | $371K | Buy |
+30,000
| New | +$346K | 0.01% | 657 |
|
Other funds holding EW
VCM
VPM
Marshall Wace's EW Position: Q1 2026 in Review
Marshall Wace reduced its Edwards Lifesciences (EW) stake by 66% in Q1 2026, selling an estimated $324M and leaving 1,996,377 shares worth $160M. The position accounts for 0.16% of the portfolio, ranked #98.
Marshall Wace first reported a position in EW in Q1 2014 and has held it in 45 quarters since. The position peaked at $539M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Marshall Wace held 1,996,377 shares of Edwards Lifesciences worth $160M as of Q1 2026.
- Marshall Wace sold 3,929,250 Edwards Lifesciences shares in Q1 2026, an estimated $324M.
- Edwards Lifesciences made up 0.16% of Marshall Wace's portfolio in Q1 2026, its #98 holding.
- Marshall Wace first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 45 quarters since.
- Marshall Wace's Edwards Lifesciences position peaked at $539M in Q2 2025.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.